For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221005:nRSE7596Ba&default-theme=true
RNS Number : 7596B Spectral MD Holdings, Ltd. 05 October 2022
Spectral MD Holdings, Ltd
("Spectral MD" or the "Company")
Burn Image Assessment Study ("BIAS") Results
Study assesses Emergency Medicine Physicians' ability to measure burn depth
LONDON, U.K. AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company with proprietary AI algorithms and optical
technology for faster and more accurate treatment decisions in wound care,
announces results from its Burn Image Assessment Study (BIAS).
Over one million people in the US and 250,000 in the UK seek evaluation for
burn injuries in emergent or urgent care settings every year. A major
component of the initial evaluation includes burn wound assessment. Literature
shows that burn care providers typically assess the depth of burn wounds
incorrectly in about 25-30% of injuries, partly because burn wound evaluation
has no adjunctive labs to aid in the determination of healing versus
non-healing burn wounds.
The objective of the Burn Injury Assessment Study (BIAS) is to obtain data in
assessment of burn depth by experts across the spectrum of Emergency Medicine
(EM) providers. BIAS collected data from emergency room providers at national
conferences. Using a tablet-based data entry device, emergency medicine
participants enrolled in the study completed a brief questionnaire followed by
a series of five scenarios of thermal burn injuries each with images from
American Burn Association (ABA)-verified burn centers. Participants were asked
to provide an overall treatment recommendation for each burn scenario. In
addition, they were asked to draw the regions of non-healing burn wound areas
within the provided images. Their performance was evaluated by comparing their
drawings with healing/non-healing areas pre-established by burn expert
review of each burns' 21-day healing assessment.
Dr. Jeff Carter, Chief Medical Consultant of Spectral MD, and Treasurer of the
American Burn Association presented the results in a podium presentation
titled, "Results from the Emergency Medicine Burn Injury Assessment Study" at
the American College of Emergency Physicians Scientific Assembly on 2 October,
2022.
The results from this study indicated that in reviewing pictures of burn
wounds that were so severe they would not have healed, emergency department
(ED) practitioners selected that no surgery was needed and advised treatment
with local wound care in 82% of patients. This would have resulted in surgical
delays in four out of five patients. For healing wounds, ED practitioners
selected local wound care in only 31% of the images. When matched pixel for
pixel, ED practitioners had an accuracy of 74%, meaning that about a quarter
of the wounds were inaccurately assessed. This is well below the current
performance of Spectral MD's DeepView™ Wound Imaging System.
Dr. Jeff Carter stated: "It is surprising to find that 31% of clinical
judgment suggested that surgery or referral was necessary for burns that would
actually heal with local wound care, which leads to unnecessary surgery and
waste of resources."
This study emphasizes the unmet clinical need for technologies which can
improve evaluation of burn wound healing. In a natural disaster or mass
casualty incident, large numbers of burn casualties could overwhelm an already
strained healthcare system, and EM providers would be called upon to perform
large volumes of burn wound assessment. Improvements in evaluating burn wound
healing are essential to aid emergency room providers in the appropriate
treatment of burn-injured patients. The BIAS results further support the
Company's belief that the DeepView™ Wound Imaging System will be
transformative in improving the current standard of care, resulting in faster
application of advanced therapy, better wound healing, and meaningful clinical
outcomes.
This project has been supported in whole or in part with federal funds from
the Department of Health and Human Services; Administration for Strategic
Preparedness and Response (ASPR (https://aspr.hhs.gov/Pages/Home.aspx) );
Biomedical Advanced Research and Development Authority (BARDA), under
contract number 75A50119C00033.
Learn more about BARDA: https://www.medicalcountermeasures.gov/
(https://www.medicalcountermeasures.gov/)
Funding support for DeepView®'s use in burn triage and treatment decisions
has also been provided by U.S. National Science Foundation (NSF), U.S.
National Institutes of Health (NIH) and U.S. Defense Health Agency (DHA).
For further information please contact:
Spectral MD Holdings, Ltd. investors.spectralmd.com
Wensheng Fan, Chief Executive Officer via Walbrook PR
Nils Windler, Chief Financial Officer
Walbrook PR Ltd (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
Paul McManus / Louis Ashe-Jepson Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393
Alice Woodings +44 (0)7407 804 654
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(®)
Wound Imaging System.
www.spectralmd.com
info@spectralmd.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAFLFSSIRLSIIF